))
ACRUX LIMITED (ACR) - Transforming Topical Pharmaceuticals: CEO Michael Kotsanis on FDA Approvals, Market Strategy, and R&D Innovations
Manage episode 433896279 series 3570035
Andrew Musgrave에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Andrew Musgrave 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Curious about the future of topical pharmaceuticals? Michael Kotsanis, CEO of Acrux Limited, joins us to uncover the company's strategic endeavors and recent successes. With over 25 years of industry experience, Michael offers valuable insights into Acrux’s focus on developing and commercializing topical generic products for the lucrative US market, valued at $16 billion. He also shares the exciting news of their recent launch of Dapsone 5% Gel and the promising market response, along with updates on three other products currently under FDA review.
Get a behind-the-scenes look at Acrux’s robust research and development efforts, supported by their GMP-licensed facility and collaborations with contract manufacturers worldwide. Learn about the intricate process of drug approval and how Acrux aims to build a sustainable revenue stream through consistent product submissions and launches. This episode is packed with fascinating details about the competitive pharmaceutical landscape and Acrux's future prospects. Don't miss this in-depth conversation with one of the industry's key players!
57 에피소드
공유
